1
|
Miller KD, Siegel RL, Lin CC, Mariotto AB,
Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer
treatment and survivorship statistics, 2016. CA Cancer J Clin.
66:271–289. 2016. View Article : Google Scholar : PubMed/NCBI
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
3
|
Torre LA, Sauer AM, Chen MS Jr,
Kagawa-Singer M, Jemal A and Siegel RL: Cancer statistics for Asian
Americans, Native Hawaiians, and Pacific Islanders, 2016:
Converging incidence in males and females. CA Cancer J Clin.
66:182–202. 2016. View Article : Google Scholar : PubMed/NCBI
|
4
|
Stangelberger A, Waldert M and Djavan B:
Prostate cancer in elderly men. Rev Urol. 10:111–119.
2008.PubMed/NCBI
|
5
|
Debes JD and Tindall DJ: Mechanisms of
androgen-refractory prostate cancer. N Engl J Med. 351:1488–1490.
2004. View Article : Google Scholar : PubMed/NCBI
|
6
|
Schröder FH: Progress in understanding
androgen-independent prostate cancer (AIPC): A review of potential
endocrine-mediated mechanisms. Eur Urol. 53:1129–1137. 2008.
View Article : Google Scholar : PubMed/NCBI
|
7
|
Engelberg D: Stress-activated protein
kinases-tumor suppressors or tumor initiators? Semin Cancer Biol.
14:271–282. 2004. View Article : Google Scholar : PubMed/NCBI
|
8
|
Dent P, Yacoub A, Fisher PB, Hagan MP and
Grant S: MAPK pathways in radiation responses. Oncogene.
22:5885–5896. 2003. View Article : Google Scholar : PubMed/NCBI
|
9
|
Weldon CB, Scandurro AB, Rolfe KW, Clayton
JL, Elliott S, Butler NN, Melnik LI, Alam J, McLachlan JA, Jaffe
BM, et al: Identification of mitogen-activated protein kinase
kinase as a chemoresistant pathway in MCF-7 cells by using gene
expression microarray. Surgery. 132:293–301. 2002. View Article : Google Scholar : PubMed/NCBI
|
10
|
Esparis-Ogando A, Diaz-Rodriguez E,
Montero JC, Yuste L, Crespo P and Pandiella A: Erk5 participates in
neuregulin signal transduction and is constitutively active in
breast cancer cells overexpressing ErbB2. Mol Cell Biol.
22:270–285. 2002. View Article : Google Scholar : PubMed/NCBI
|
11
|
Mehta PB, Jenkins BL, McCarthy L, Thilak
L, Robson CN, Neal DE and Leung HY: MEK5 overexpression is
associated with metastatic prostate cancer, and stimulates
proliferation, MMP-9 expression and invasion. Oncogene.
22:1381–1389. 2003. View Article : Google Scholar : PubMed/NCBI
|
12
|
Hayashi M and Lee JD: Role of the
BMK1/ERK5 signaling pathway: Lessons from knockout mice. J Mol Med.
82:800–808. 2004. View Article : Google Scholar : PubMed/NCBI
|
13
|
Xiong Y, Zhang L and Wang T:
Phosphorylation of BMK1 induces prostatic carcinoma cell
proliferation by promoting entry into the S phase of the cell
cycle. Oncol Lett. 11:99–104. 2016. View Article : Google Scholar : PubMed/NCBI
|
14
|
Finlin BS, Gau CL, Murphy GA, Shao H,
Kimel T, Seitz RS, Chiu YF, Botstein D, Brown PO, Der CJ, et al:
RERG is a novel ras-related, estrogen-regulated and
growth-inhibitory gene in breast cancer. J Biol Chem.
276:42259–42267. 2001. View Article : Google Scholar : PubMed/NCBI
|
15
|
Sørlie T, Perou CM, Tibshirani R, Aas T,
Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey
SS, et al: Gene expression patterns of breast carcinomas
distinguish tumor subclasses with clinical implications. Proc Natl
Acad Sci USA. 98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI
|
16
|
Key MD, Andres DA, Der CJ and Repasky GA:
Characterization of RERG An estrogen-regulated tumor
suppressor gene. Methods Enzymol. 407:513–527. 2006. View Article : Google Scholar : PubMed/NCBI
|
17
|
Habashy HO, Powe DG, Glaab E, Ball G,
Spiteri I, Krasnogor N, Garibaldi JM, Rakha EA, Green AR, Caldas C,
et al: RERG (Ras-like, oestrogen-regulated, growth-inhibitor)
expression in breast cancer: A marker of ER-positive luminal-like
subtype. Breast Cancer Res Treat. 128:315–326. 2011. View Article : Google Scholar : PubMed/NCBI
|
18
|
Zhao W, Ma N, Wang S, Mo Y, Zhang Z, Huang
G, Midorikawa K, Hiraku Y, Oikawa S, Murata M and Takeuchi K:
RERG suppresses cell proliferation, migration and
angiogenesis through ERK/NF-κB signaling pathway in nasopharyngeal
carcinoma. J Exp Clin Cancer Res. 36:882017. View Article : Google Scholar : PubMed/NCBI
|
19
|
Luo X, Huang R, Sun H, Liu Y, Bi H, Li J,
Yu H, Sun J, Lin S, Cui B, et al: Methylation of a panel of genes
in peripheral blood leukocytes is associated with colorectal
cancer. Sci Rep. 6:299222016. View Article : Google Scholar : PubMed/NCBI
|
20
|
Oster B, Thorsen K, Lamy P, Wojdacz TK,
Hansen LL, Birkenkamp-Demtröder K, Sørensen KD, Laurberg S, Orntoft
TF and Andersen CL: Identification and validation of highly
frequent CpG island hypermethylation in colorectal adenomas and
carcinomas. Int J Cancer. 129:2855–2866. 2011. View Article : Google Scholar : PubMed/NCBI
|
21
|
Yang Q, Deng X, Lu B, Cameron M, Fearns C,
Patricelli MP, Yates JR III, Gray NS and Lee JD: Pharmacological
inhibition of BMK1 suppresses tumor growth through promyelocytic
leukemia protein. Cancer Cell. 18:258–267. 2010. View Article : Google Scholar : PubMed/NCBI
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2ΔΔCT method. Methods.
25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
23
|
Annabi B, Lachambre MP, Plouffe K,
Sartelet H and Béliveau R: Modulation of invasive properties of
CD133+ glioblastoma stem cells: A role for MT1-MMP in
bioactive lysophospholipid signaling. Mol Carcinog. 48:910–919.
2009. View
Article : Google Scholar : PubMed/NCBI
|
24
|
Wang YB, Zhao XH, Li G, Zheng JH and Qiu
W: MicroRNA-184 inhibits proliferation and promotes apoptosis of
human colon cancer SW480 and HCT116 cells by downregulating C-MYC
and BCL-2. J Cell Biochem. 119:1702–1715. 2018. View Article : Google Scholar : PubMed/NCBI
|
25
|
Peng Z, Wang Y, Fan J, Lin X, Liu C, Xu Y,
Ji W, Yan C and Su C: Costunolide and dehydrocostuslactone
combination treatment inhibit breast cancer by inducing cell cycle
arrest and apoptosis through c-Myc/p53 and AKT/14-3-3 pathway. Sci
Rep. 7:412542017. View Article : Google Scholar : PubMed/NCBI
|
26
|
Wang Q, Liu S, Tang Y, Liu Q and Yao Y:
MPT64 protein from Mycobacterium tuberculosis inhibits apoptosis of
macrophages through NF-κB-miRNA21-Bcl-2 pathway. PLoS One.
9:e1009492014. View Article : Google Scholar : PubMed/NCBI
|
27
|
Yen TH, Hsieh CL, Liu TT, Huang CS, Chen
YC, Chuang YC, Lin SS and Hsu FT: Amentoflavone induces apoptosis
and inhibits NF-ĸB-modulated anti-apoptotic signaling in
glioblastoma cells. In vivo. 32:279–285. 2018.PubMed/NCBI
|
28
|
Pan L, Li Y, Zhang HY, Zheng Y, Liu XL, Hu
Z, Wang Y, Wang J, Cai YH, Liu Q, et al: DHX15 is associated with
poor prognosis in acute myeloid leukemia (AML) and regulates cell
apoptosis via the NF-κB signaling pathway. Oncotarget.
8:89643–89654. 2017. View Article : Google Scholar : PubMed/NCBI
|
29
|
Spiering D, Schmolke M, Ohnesorge N,
Schmidt M, Goebeler M, Wegener J, Wixler V and Ludwig S: MEK5/ERK5
signaling modulates endothelial cell migration and focal contact
turnover. J Biol Chem. 284:24972–24980. 2009. View Article : Google Scholar : PubMed/NCBI
|
30
|
Kato Y, Tapping RI, Huang S, Watson MH,
Ulevitch RJ and Lee JD: Bmk1/Erk5 is required for cell
proliferation induced by epidermal growth factor. Nature.
395:713–716. 1998. View
Article : Google Scholar : PubMed/NCBI
|
31
|
Zhao Z, Geng J, Ge Z, Wang W, Zhang Y and
Kang W: Activation of ERK5 in angiotensin II-induced hypertrophy of
human aortic smooth muscle cells. Mol Cell Biochem. 322:171–178.
2009. View Article : Google Scholar : PubMed/NCBI
|
32
|
Lochhead PA, Gilley R and Cook SJ: ERK5
and its role in tumour development. Biochem Soc Trans. 40:251–256.
2012. View Article : Google Scholar : PubMed/NCBI
|
33
|
Antoon JW, Martin EC, Lai R, Salvo VA,
Tang Y, Nitzchke AM, Elliott S, Nam SY, Xiong W, Rhodes LV, et al:
MEK5/ERK5 signaling suppresses estrogen receptor expression and
promotes hormone-independent tumorigenesis. PLoS One. 8:e692912013.
View Article : Google Scholar : PubMed/NCBI
|
34
|
Sticht C, Freier K, Knöpfle K,
Flechtenmacher C, Pungs S, Hofele C, Hahn M, Joos S and Lichter P:
Activation of MAP kinase signaling through ERK5 but not ERK1
expression is associated with lymph node metastases in oral
squamous cell carcinoma (OSCC). Neoplasia. 10:462–470. 2008.
View Article : Google Scholar : PubMed/NCBI
|
35
|
McCracken SR, Ramsay A, Heer R, Mathers
ME, Jenkins BL, Edwards J, Robson CN, Marquez R, Cohen P and Leung
HY: Aberrant expression of extracellular signal-regulated kinase 5
in human prostate cancer. Oncogene. 27:2978–2988. 2008. View Article : Google Scholar : PubMed/NCBI
|
36
|
Ramsay AK, McCracken SR, Soofi M, Fleming
J, Yu AX, Ahmad I, Morland R, Machesky L, Nixon C, Edwards DR, et
al: ERK5 signalling in prostate cancer promotes an invasive
phenotype. Br J Cancer. 104:664–672. 2011. View Article : Google Scholar : PubMed/NCBI
|
37
|
Ho JY, Hsu RJ, Liu JM, Chen SC, Liao GS,
Gao HW and Yu CP: MicroRNA-382-5p aggravates breast cancer
progression by regulating the RERG/Ras/ERK signaling axis.
Oncotarget. 8:22443–22459. 2017. View Article : Google Scholar : PubMed/NCBI
|
38
|
Cude K, Wang Y, Choi HJ, Hsuan SL, Zhang
H, Wang CY and Xia Z: Regulation of the G2-M cell cycle progression
by the ERK5-NFkappaB signaling pathway. J Cell Biol. 177:253–264.
2007. View Article : Google Scholar : PubMed/NCBI
|
39
|
Yuan Y, Anbalagan D, Lee LH, Samy RP,
Shanmugam MK, Kumar AP, Sethi G, Lobie PE and Lim LH: ANXA1
inhibits miRNA-196a in a negative feedback loop through NF-κB and
c-Myc to reduce breast cancer proliferation. Oncotarget.
7:27007–27020. 2016. View Article : Google Scholar : PubMed/NCBI
|
40
|
Lin ML, Lu YC, Chung JG, Wang SG, Lin HT,
Kang SE, Tang CH, Ko JL and Chen SS: Down-regulation of MMP-2
through the p38 MAPK-NF-kappaB-dependent pathway by aloe-emodin
leads to inhibition of nasopharyngeal carcinoma cell invasion. Mol
Carcinog. 49:783–797. 2010.PubMed/NCBI
|